Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma
Metrics: PDF 300 views | HTML 470 views | ?
Kazuyoshi Yanagihara1,5, Takanori Kubo2, Keichiro Mihara3, Takeshi Kuwata4, Atsushi Ochiai1, Toshio Seyama2, and Hiroshi Yokozaki5
1Division of Biomarker Discovery, Exploratory Oncology and Clinical Trial Center, National Cancer Center, Chiba, Japan
2Department of Life Sciences, Yasuda Women’s University Faculty of Pharmacy, Hiroshima, Japan
3Department of Hematology/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
4Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan
5Division of Pathology, Department of Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
Kazuyoshi Yanagihara, email: firstname.lastname@example.org
Keywords: BRAFV600E mutation; duodenal neuroendocrine carcinoma; established cell line; orthotopic animal model; rare human cancer
Received: August 28, 2018 Accepted: November 01, 2018 Published: November 23, 2018
Poorly differentiated neuroendocrine carcinoma of the duodenum (D-NEC) is a rare cancer with poor prognosis. However, a D-NEC cell line has not yet been established to study the disease. We established a cell line, TCC-NECT-2, from the ascites tumor of a 59-year-old male Japanese patient with D-NEC. TCC-NECT-2 was positive for neuroendocrine markers, chromogranin A (CGA), cluster of differentiation 56 (CD56/NCAM), synaptophysin (SYN/p38), and neuron specific enolase (NSE). Cells exhibited retinoblastoma (RB) protein loss. Orthotopic implantation of TCC-NECT-2 cells into nu/nu mice resulted in tumor formation (incidence = 83.3%) with neuroendocrine characteristics, metastasis, and weight loss. BRAFV600E and TP53 mutations and C-MYC gene amplification were also observed in TCC-NECT-2. BRAFV600E-expressing TCC-NECT-2 cells were sensitive to BRAF inhibitor vemurafenib, and especially dabrafenib, in vitro, and were strongly inhibited in a dose-dependent manner. Dabrafenib treatment (30 mg/kg) in a xenograft model for 14 days significantly suppressed tumor growth (percent tumor growth inhibition, TGI% = 48.04). An enhanced therapeutic effect (TGI% = 95.81) was observed on combined treatment of dabrafenib and irinotecan (40 mg/kg). Therefore, TCC-NECT-2, the first reported cell line derived from D-NEC, might serve as a useful model to study the basic biology of D-NEC and translational applications for treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.